Current status and prospects of the application of Mendelian randomization in pancreatic cancer research

Kaihao DU; Lizhao HOU; Lanminghui LUO; Xiaoge DONG; Wei JIANG; Zhan WANG

doi:10.12449/JCH241033

Volume 40 Issue 10

Oct. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(10): 2127-2136

PDF( 1051 KB)

Current status and prospects of the application of Mendelian randomization in pancreatic cancer research

DOI: 10.12449/JCH241033

1.
Clinical Medical College，Qinghai University，Xining 810000，China
2a.
Department of General Surgery，The Affiliated Hospital of Qinghai University，Xining 810000，China
2b.
Department of Medical Engineering Integration and Translational Application，The Affiliated Hospital of Qinghai University，Xining 810000，China

Research funding:

National Natural Science Foundation of China (82160131);

Qinghai Provincial Department of Science and Technology Project (2021-ZJ-963Q)

More Information

Corresponding author: WANG Zhan， ufofu01@163.com （ORCID： 0000-0002-4225-8136）
Received Date: 2024-01-21
Accepted Date: 2024-04-19
Published Date: 2024-10-25

Abstract

Abstract

Pancreatic cancer often has an insidious onset and difficulties in treatment， with various limitations in early diagnosis and treatment. This article reviews the application of Mendelian randomization （MR） in exploring the risk factors for pancreatic cancer， with a special focus on the causal relationships of factors such as gut microbiota， lifestyle， and metabolic diseases. Leveraging data from large-scale genome-wide association studies （GWAS）， MR analysis has revealed several biomarkers associated with the risk of pancreatic cancer. The two-sample MR approach is commonly used in current research， including the methods such as Inverse Variance Weighted， Weighted Median， and MR-Egger， which helps to explain the causal network of the disease from a genetic perspective. While MR strategy provides a new perspective for understanding the etiology of pancreatic cancer， caution is still needed in data synthesis， selection of instrumental variables， and pleiotropy assessment. The use of emerging analytical models such as BWMR， CAUSE， and MVMR offers new possibilities for the comprehensive evaluation of multiple risk factors and their interaction. In the future， with the combination of these methods and the ever-increasing genetic epidemiological data， MR analysis is expected to provide more solid evidence for identifying potential therapeutic targets for pancreatic cancer and formulating prevention strategies.
- Pancreatic Neoplasms,
- Mendelian Randomization Analysis,
- Causality

FullText(HTML)

References(93)

References

[1]	ARNOLD M, ABNET CC, NEALE RE, et al. Global burden of 5 major types of gastrointestinal cancer[J]. Gastroenterology, 2020, 159( 1): 335- 349. e 15. DOI: 10.1053/j.gastro.2020.02.068.
[2]	ILIC M, ILIC I. Epidemiology of pancreatic cancer[J]. World J Gastroenterol, 2016, 22( 44): 9694- 9705. DOI: 10.3748/wjg.v22.i44.9694.
[3]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[4]	FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136( 5): E359- E386. DOI: 10.1002/ijc.29210.
[5]	HIDALGO M, CASCINU S, KLEEFF J, et al. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes[J]. Pancreatology, 2015, 15( 1): 8- 18. DOI: 10.1016/j.pan.2014.10.001.
[6]	General Office of National Health Commission. Standard for diagnosis and treatment of pancreatic cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 5): 1006- 1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007. 国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 5): 1006- 1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007.
[7]	MILLIKAN KW, DEZIEL DJ, SILVERSTEIN JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas[J]. Am Surg, 1999, 65( 7): 618-623; discussion 623-624.
[8]	KOLBEINSSON HM, CHANDANA S, WRIGHT GP, et al. Pancreatic cancer: A review of current treatment and novel therapies[J]. J Invest Surg, 2023, 36( 1): 2129884. DOI: 10.1080/08941939.2022.2129884.
[9]	PARKIN DM, BOYD L, WALKER LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010[J]. Br J Cancer, 2011, 105( Suppl 2): S77- S81. DOI: 10.1038/bjc.2011.489.
[10]	WILLETT WC. Diet and cancer[J]. Oncol, 2000, 5( 5): 393- 404. DOI: 10.1634/theoncologist.5-5-393.
[11]	BOSETTI C, BERTUCCIO P, NEGRI E, et al. Pancreatic cancer: Overview of descriptive epidemiology[J]. Mol Carcinog, 2012, 51( 1): 3- 13. DOI: 10.1002/mc.20785.
[12]	ANAND P, KUNNUMAKKARA AB, SUNDARAM C, et al. Cancer is a preventable disease that requires major lifestyle changes[J]. Pharm Res, 2008, 25( 9): 2097- 2116. DOI: 10.1007/s11095-008-9661-9.
[13]	WANG LN, ZHANG ZF. Mendelian randomization approach, used for causal inferences[J]. Chin J Epidemiol, 2017, 38( 4): 547- 552. DOI: 10.3760/cma.j.issn.0254-6450.2017.04.027. 王莉娜, ZHANG ZuoFeng. 孟德尔随机化法在因果推断中的应用[J]. 中华流行病学杂志, 2017, 38( 4): 547- 552. DOI: 10.3760/cma.j.issn.0254-6450.2017.04.027.
[14]	DAVEY SMITH G, HEMANI G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies[J]. Hum Mol Genet, 2014, 23( R1): R89- R98. DOI: 10.1093/hmg/ddu328.
[15]	ZHENG J, BAIRD D, BORGES MC, et al. Recent developments in Mendelian randomization studies[J]. Curr Epidemiol Rep, 2017, 4( 4): 330- 345. DOI: 10.1007/s40471-017-0128-6.
[16]	LAWLOR DA, HARBORD RM, STERNE JA, et al. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology[J]. Stat Med, 2008, 27( 8): 1133- 1163. DOI: 10.1002/sim.3034.
[17]	VERBANCK M, CHEN CY, NEALE B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet, 2018, 50( 5): 693- 698. DOI: 10.1038/s41588-018-0099-7.
[18]	BOWDEN J, DAVEY SMITH G, BURGESS S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44( 2): 512- 525. DOI: 10.1093/ije/dyv080.
[19]	ZHAO J, MING JS, HU XH, et al. Bayesian weighted Mendelian randomization for causal inference based on summary statistics[J]. Bioinformatics, 2020, 36( 5): 1501- 1508. DOI: 10.1093/bioinformatics/btz749.
[20]	LAWLOR DA. Commentary: Two-sample Mendelian randomization: Opportunities and challenges[J]. Int J Epidemiol, 2016, 45( 3): 908- 915. DOI: 10.1093/ije/dyw127.
[21]	BURGESS S, BUTTERWORTH A, THOMPSON SG. Mendelian randomization analysis with multiple genetic variants using summarized data[J]. Genet Epidemiol, 2013, 37( 7): 658- 665. DOI: 10.1002/gepi.21758.
[22]	YU TQ, XU WT, SU YN, et al. Basic principles, methods and limitations of Mendelian randomization studies[J]. Chin J Evid-Based Med, 2021, 21( 10): 1227- 1234. DOI: 10.7507/1672-2531.202107008. 于天琦, 徐文涛, 苏雅娜, 等. 孟德尔随机化研究基本原理、方法和局限性[J]. 中国循证医学杂志, 2021, 21( 10): 1227- 1234. DOI: 10.7507/1672-2531.202107008.
[23]	BOWDEN J, DAVEY SMITH G, HAYCOCK PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted Median estimator[J]. Genet Epidemiol, 2016, 40( 4): 304- 314. DOI: 10.1002/gepi.21965.
[24]	BOWDEN J, DEL GRECO MF, MINELLI C, et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: The role of the I₂ statistic[J]. Int J Epidemiol, 2016, 45( 6): 1961- 1974. DOI: 10.1093/ije/dyw220.
[25]	JIANG ZC, MOU YP, WANG HJ, et al. Causal effect between gut microbiota and pancreatic cancer: A two-sample Mendelian randomization study[J]. BMC Cancer, 2023, 23( 1): 1091. DOI: 10.1186/s12885-023-11493-y.
[26]	ZHU SJ, DING Z. Association between gut microbiota and seven gastrointestinal diseases: A Mendelian randomized study[J]. J Gene Med, 2024, 26( 1): e3623. DOI: 10.1002/jgm.3623.
[27]	ZHANG XN, ZHAO H, MAN JY, et al. Investigating causal associations of diet-derived circulating antioxidants with the risk of digestive system cancers: A Mendelian randomization study[J]. Nutrients, 2022, 14( 15): 3237. DOI: 10.3390/nu14153237.
[28]	MIN Y, LIU ZR, LI RD, et al. Association between inflammatory bowel disease and pancreatic cancer: Results from the two-sample Mendelian randomization study[J]. Front Oncol, 2023, 13: 1155123. DOI: 10.3389/fonc.2023.1155123.
[29]	PIERCE BL, AHSAN H, VANDERWEELE TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants[J]. Int J Epidemiol, 2011, 40( 3): 740- 752. DOI: 10.1093/ije/dyq151.
[30]	ADAK A, KHAN MR. An insight into gut microbiota and its functionalities[J]. Cell Mol Life Sci, 2019, 76( 3): 473- 493. DOI: 10.1007/s00018-018-2943-4.
[31]	de VOS WM, TILG H, van HUL M, et al. Gut microbiome and health: Mechanistic insights[J]. Gut, 2022, 71( 5): 1020- 1032. DOI: 10.1136/gutjnl-2021-326789.
[32]	LIU MY. Arid1a: A gatekeeper in the development of pancreatic cancer from a rare precursor lesion[J]. Gastroenterology, 2022, 163( 2): 371- 373. DOI: 10.1053/j.gastro.2022.05.046.
[33]	CAI J, CHEN HD, LU M, et al. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J]. Cancer Lett, 2021, 520: 1- 11. DOI: 10.1016/j.canlet.2021.06.027.
[34]	TONG Y, GAO HR, QI QC, et al. High fat diet, gut microbiome and gastrointestinal cancer[J]. Theranostics, 2021, 11( 12): 5889- 5910. DOI: 10.7150/thno.56157.
[35]	COHEN LJ, CHO JH, GEVERS D, et al. Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases[J]. Gastroenterology, 2019, 156( 8): 2174- 2189. DOI: 10.1053/j.gastro.2019.03.017.
[36]	WONG SH, YU J. Gut microbiota in colorectal cancer: Mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 11): 690- 704. DOI: 10.1038/s41575-019-0209-8.
[37]	MA C, HAN MJ, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360( 6391): eaan5931. DOI: 10.1126/science.aan5931.
[38]	ERTZ-ARCHAMBAULT N, KEIM P, von HOFF D. Microbiome and pancreatic cancer: A comprehensive topic review of literature[J]. World J Gastroenterol, 2017, 23( 10): 1899- 1908. DOI: 10.3748/wjg.v23.i10.1899.
[39]	YANG QY, ZHANG JH, ZHU Y. Potential roles of the gut microbiota in pancreatic carcinogenesis and therapeutics[J]. Front Cell Infect Microbiol, 2022, 12: 872019. DOI: 10.3389/fcimb.2022.872019.
[40]	PUSHALKAR S, HUNDEYIN M, DALEY D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J]. Cancer Discov, 2018, 8( 4): 403- 416. DOI: 10.1158/2159-8290.CD-17-1134.
[41]	SETHI V, KURTOM S, TARIQUE M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response[J]. Gastroenterology, 2018, 155( 1): 33- 37. e 6. DOI: 10.1053/j.gastro.2018.04.001.
[42]	YU Q, NEWSOME RC, BEVERIDGE M, et al. Intestinal microbiota modulates pancreatic carcinogenesis through intratumoral natural killer cells[J]. Gut Microbes, 2022, 14( 1): 2112881. DOI: 10.1080/19490976.2022.2112881.
[43]	CARINI F, MAZZOLA M, RAPPA F, et al. Colorectal carcinogenesis: Role of oxidative stress and antioxidants[J]. Anticancer Res, 2017, 37( 9): 4759- 4766. DOI: 10.21873/anticanres.11882.
[44]	SHIMIZU Y, TAMURA T, KEMMOCHI A, et al. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model[J]. J Gastroenterol Hepatol, 2021, 36( 3): 800- 810. DOI: 10.1111/jgh.15239.
[45]	AKBARI A, MAJD HM, RAHNAMA R, et al. Cross-talk between oxidative stress signaling and microRNA regulatory systems in carcinogenesis: Focused on gastrointestinal cancers[J]. Biomedecine Pharmacother, 2020, 131: 110729. DOI: 10.1016/j.biopha.2020.110729.
[46]	KLAUNIG JE. Oxidative stress and cancer[J]. Curr Pharm Des, 2018, 24( 40): 4771- 4778. DOI: 10.2174/1381612825666190215121712.
[47]	YIN LL, YAN HH, CHEN KD, et al. Diet-derived circulating antioxidants and risk of digestive system tumors: A Mendelian randomization study[J]. Nutrients, 2022, 14( 16): 3274. DOI: 10.3390/nu14163274.
[48]	SEMPERE-RUBIO N, AGUAS M, FAUBEL R. Association between chronotype, physical activity and sedentary behaviour: A systematic review[J]. Int J Environ Res Public Health, 2022, 19( 15): 9646. DOI: 10.3390/ijerph19159646.
[49]	MAZRI FH, MANAF ZA, SHAHAR S, et al. The association between chronotype and dietary pattern among adults: A scoping review[J]. Int J Environ Res Public Health, 2019, 17( 1): 68. DOI: 10.3390/ijerph17010068.
[50]	SROUR B, PLANCOULAINE S, ANDREEVA VA, et al. Circadian nutritional behaviours and cancer risk: New insights from the NutriNet-santé prospective cohort study: Disclaimers[J]. Int J Cancer, 2018, 143( 10): 2369- 2379. DOI: 10.1002/ijc.31584.
[51]	CARASSO S, FISHMAN B, LASK LS, et al. Metagenomic analysis reveals the signature of gut microbiota associated with human chronotypes[J]. FASEB J, 2021, 35( 11): e22011. DOI: 10.1096/fj.202100857RR.
[52]	MENG CT, BAI CM, BROWN TD, et al. Human gut microbiota and gastrointestinal cancer[J]. Genomics Proteomics Bioinformatics, 2018, 16( 1): 33- 49. DOI: 10.1016/j.gpb.2017.06.002.
[53]	FENG Q, LIANG SS, JIA HJ, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence[J]. Nat Commun, 2015, 6: 6528. DOI: 10.1038/ncomms7528.
[54]	YUAN S, MASON AM, TITOVA OE, et al. Morning chronotype and digestive tract cancers: Mendelian randomization study[J]. Int J Cancer, 2023, 152( 4): 697- 704. DOI: 10.1002/ijc.34284.
[55]	RISK FACTOR COLLABORATION NCD-RISC) NCD. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants[J]. Lancet, 2016, 387( 10027): 1513- 1530. DOI: 10.1016/S0140-6736(16)00618-8.
[56]	TSILIDIS KK, KASIMIS JC, LOPEZ DS, et al. Type 2 diabetes and cancer: Umbrella review of meta-analyses of observational studies[J]. BMJ, 2015, 350: g7607. DOI: 10.1136/bmj.g7607.
[57]	PEARSON-STUTTARD J, PAPADIMITRIOU N, MARKOZANNES G, et al. Type 2 diabetes and cancer: An umbrella review of observational and Mendelian randomization studies[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30( 6): 1218- 1228. DOI: 10.1158/1055-9965.EPI-20-1245.
[58]	SHEN BY, LI YY, SHENG CS, et al. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and Mendelian randomization study[J]. Lancet Reg Health West Pac, 2023, 30: 100596. DOI: 10.1016/j.lanwpc.2022.100596.
[59]	INCIO J, LIU H, SUBOJ P, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy[J]. Cancer Discov, 2016, 6( 8): 852- 869. DOI: 10.1158/2159-8290.CD-15-1177.
[60]	PARK JH, AMERI AH, DEMPSEY KE, et al. Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation[J]. EMBO J, 2021, 40( 7): e106151. DOI: 10.15252/embj.2020106151.
[61]	YUDKIN JS, STEHOUWER CD, EMEIS JJ, et al. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?[J]. Arterioscler Thromb Vasc Biol, 1999, 19( 4): 972- 978. DOI: 10.1161/01.atv.19.4.972.
[62]	XU HY, BARNES GT, YANG Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance[J]. J Clin Invest, 2003, 112( 12): 1821- 1830. DOI: 10.1172/JCI19451.
[63]	SINGH A, MAYENGBAM SS, YADUVANSHI H, et al. Obesity programs macrophages to support cancer progression[J]. Cancer Res, 2022, 82( 23): 4303- 4312. DOI: 10.1158/0008-5472.CAN-22-1257.
[64]	XIA B, HE QS, PAN YH, et al. Metabolic syndrome and risk of pancreatic cancer: A population-based prospective cohort study[J]. Int J Cancer, 2020, 147( 12): 3384- 3393. DOI: 10.1002/ijc.33172.
[65]	LI ZQ, JIN LQ, XIA L, et al. Body mass index, C-reactive protein, and pancreatic cancer: A Mendelian randomization analysis to investigate causal pathways[J]. Front Oncol, 2023, 13: 1042567. DOI: 10.3389/fonc.2023.1042567.
[66]	SON J, LYSSIOTIS CA, YING HQ, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway[J]. Nature, 2013, 496( 7443): 101- 105. DOI: 10.1038/nature12040.
[67]	CHEUNG PK, MA MH, TSE HF, et al. The applications of metabolomics in the molecular diagnostics of cancer[J]. Expert Rev Mol Diagn, 2019, 19( 9): 785- 793. DOI: 10.1080/14737159.2019.1656530.
[68]	XIE GX, LU LG, QIU YP, et al. Plasma metabolite biomarkers for the detection of pancreatic cancer[J]. J Proteome Res, 2015, 14( 2): 1195- 1202. DOI: 10.1021/pr501135f.
[69]	LI QX, JIN M, LIU YH, et al. Gut microbiota: Its potential roles in pancreatic cancer[J]. Front Cell Infect Microbiol, 2020, 10: 572492. DOI: 10.3389/fcimb.2020.572492.
[70]	ZHONG H, LIU S, ZHU JJ, et al. Elucidating the role of blood metabolites on pancreatic cancer risk using two-sample Mendelian randomization analysis[J]. Int J Cancer, 2024, 154( 5): 852- 862. DOI: 10.1002/ijc.34771.
[71]	NADEEM MS, KUMAR V, AL-ABBASI FA, et al. Risk of colorectal cancer in inflammatory bowel diseases[J]. Semin Cancer Biol, 2020, 64: 51- 60. DOI: 10.1016/j.semcancer.2019.05.001.
[72]	ZHANG HM, ZHANG MM, CHEN XF, et al. Risk of malignancy in patients with inflammatory bowel disease: A population-based cohort study from China[J]. Int J Cancer, 2022, 150( 11): 1770- 1778. DOI: 10.1002/ijc.33932.
[73]	JUNG YS, HAN M, PARK S, et al. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: A nationwide population-based study[J]. J Crohns Colitis, 2017, 11( 8): 954- 962. DOI: 10.1093/ecco-jcc/jjx040.
[74]	ÅH EVERHOV, ERICHSEN R, SACHS MC, et al. Inflammatory bowel disease and pancreatic cancer: A Scandinavian register-based cohort study 1969-2017[J]. Aliment Pharmacol Ther, 2020, 52( 1): 143- 154. DOI: 10.1111/apt.15785.
[75]	LO B, ZHAO M, VIND I, et al. The risk of extraintestinal cancer in inflammatory bowel disease: A systematic review and meta-analysis of population-based cohort studies[J]. Clin Gastroenterol Hepatol, 2021, 19( 6): 1117- 1138. e 19. DOI: 10.1016/j.cgh.2020.08.015.
[76]	DENHAM W, YANG J, FINK G, et al. Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pancreatitis[J]. Gastroenterology, 1997, 113( 5): 1741- 1746. DOI: 10.1053/gast.1997.v113.pm9352880.
[77]	MARRACHE F, TU SP, BHAGAT G, et al. Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis[J]. Gastroenterology, 2008, 135( 4): 1277- 1287. DOI: 10.1053/j.gastro.2008.06.078.
[78]	TAKAHASHI R, MACCHINI M, SUNAGAWA M, et al. Interleukin-1β- induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression[J]. Gut, 2021, 70( 2): 330- 341. DOI: 10.1136/gutjnl-2019-319912.
[79]	ZHANG Y, CHEN XY, WANG HM, et al. Innate immune mediator, Interleukin-1 receptor accessory protein(IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer[J]. J Hematol Oncol, 2022, 15( 1): 70. DOI: 10.1186/s13045-022-01286-4.
[80]	TJOMSLAND V, SANDNES D, POMIANOWSKA E, et al. The TGFβ- SMAD3 pathway inhibits IL-1α induced interactions between human pancreatic stellate cells and pancreatic carcinoma cells and restricts cancer cell migration[J]. J Exp Clin Cancer Res, 2016, 35( 1): 122. DOI: 10.1186/s13046-016-0400-5.
[81]	MAKER AV, KATABI N, QIN LX, et al. Cyst fluid interleukin-1beta(IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas[J]. Clin Cancer Res, 2011, 17( 6): 1502- 1508. DOI: 10.1158/1078-0432.CCR-10-1561.
[82]	YUAN S, MIAO YY, RUAN XX, et al. Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: Mendelian randomization study[J]. Front Immunol, 2023, 14: 1240754. DOI: 10.3389/fimmu.2023.1240754.
[83]	GRECO M FD, MINELLI C, SHEEHAN NA, et al. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome[J]. Stat Med, 2015, 34( 21): 2926- 2940. DOI: 10.1002/sim.6522.
[84]	WANG X, GAO HY, ZENG YY, et al. A Mendelian analysis of the relationships between immune cells and breast cancer[J]. Front Oncol, 2024, 14: 1341292. DOI: 10.3389/fonc.2024.1341292.
[85]	MORRISON J, KNOBLAUCH N, MARCUS JH, et al. Mendelian randomization accounting for correlated and uncorrelated pleiotropic effects using genome-wide summary statistics[J]. Nat Genet, 2020, 52( 7): 740- 747. DOI: 10.1038/s41588-020-0631-4.
[86]	BARANOVA A, CAO HB, ZHANG FQ. Causal effect of COVID-19 on Alzheimer’s disease: A Mendelian randomization study[J]. J Med Virol, 2023, 95( 1): e28107. DOI: 10.1002/jmv.28107.
[87]	MICHAËLSSON M, YUAN S, MELHUS H, et al. The impact and causal directions for the associations between diagnosis of ADHD, socioeconomic status, and intelligence by use of a bi-directional two-sample Mendelian randomization design[J]. BMC Med, 2022, 20( 1): 106. DOI: 10.1186/s12916-022-02314-3.
[88]	SANDERSON E. Multivariable Mendelian randomization and mediation[J]. Cold Spring Harb Perspect Med, 2021, 11( 2): a038984. DOI: 10.1101/cshperspect.a038984.
[89]	WILLER CJ, SCHMIDT EM, SENGUPTA S, et al. Discovery and refinement of loci associated with lipid levels[J]. Nat Genet, 2013, 45( 11): 1274- 1283. DOI: 10.1038/ng.2797.
[90]	WÜRTZ P, KANGAS AJ, SOININEN P, et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: A note on Mendelian randomization studies[J]. J Am Coll Cardiol, 2013, 62( 20): 1906- 1908. DOI: 10.1016/j.jacc.2013.07.085.
[91]	BURGESS S, THOMPSON SG. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects[J]. Am J Epidemiol, 2015, 181( 4): 251- 260. DOI: 10.1093/aje/kwu283.
[92]	BURGESS S, DUDBRIDGE F, THOMPSON SG. Re:“Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects”[J]. Am J Epidemiol, 2015, 181( 4): 290- 291. DOI: 10.1093/aje/kwv017.
[93]	KEMP JP, SAYERS A, SMITH GD, et al. Using Mendelian randomization to investigate a possible causal relationship between adiposity and increased bone mineral density at different skeletal sites in children[J]. Int J Epidemiol, 2016, 45( 5): 1560- 1572. DOI: 10.1093/ije/dyw079.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (142) PDF downloads(16)

Current status and prospects of the application of Mendelian randomization in pancreatic cancer research

DOI: 10.12449/JCH241033

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Current status and prospects of the application of Mendelian randomization in pancreatic cancer research

DOI: 10.12449/JCH241033

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content